The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

Abstract Background Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors and immunomodulatory drugs. Despite these options, almost all p...

Full description

Bibliographic Details
Main Authors: Alina Striha, A. John Ashcroft, Anna Hockaday, David A. Cairns, Karen Boardman, Gwen Jacques, Cathy Williams, John A. Snowden, Mamta Garg, Jamie Cavenagh, Kwee Yong, Mark T. Drayson, Roger Owen, Mark Cook, Gordon Cook
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Trials
Subjects:
Multiple myeloma
ASCT
Augmented ASCT
Randomised
Haematology
Depth of response
Online Access:http://link.springer.com/article/10.1186/s13063-018-2524-8

Internet

http://link.springer.com/article/10.1186/s13063-018-2524-8

Similar Items